230 results on '"Laszlo, Daniele"'
Search Results
2. “Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.”
3. Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis
4. Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis
5. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project
6. Midline catheter as effective device in healthy allogeneic donors and patients without an adequate peripheral venous access for HPC collection by apheresis: Preliminary experience at IEO
7. Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research
8. A MALT lymphoma prognostic index
9. Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012
10. Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study
11. Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review
12. Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis
13. R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma
14. A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity‐score weighted multicenter approach
15. Who should be really considered as a poor mobilizer in the plerixafor era?
16. Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience
17. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma
18. Cost comparison of extracorporeal photopheresis technologies at the European Institute of Oncology
19. Leukemia Research Reports Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of multiple myeloma: high effectiveness and low toxicity. Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
20. Plerixafor and Filgrastim XM02 (Tevagastrim®) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation
21. Case report – Prolonged SARS-CoV-2 positive PCR after resolution of symptoms
22. Local Thrombolytic Therapy in Cancer Patients with Central Venous Catheter Occlusion in Urgent Need of Antiblastic Treatment: A Single Institution Experience
23. Persistent Residual Disease in t(11;18)(q21;q21) Positive Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Chemotherapy or Rituximab
24. Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkinʼs Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori Therapy
25. Tailored therapy of adult acute leukaemia in Jehovahʼs Witnesses: unjustified reluctance to treat
26. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkinʼs lymphoma
27. Second Allogeneic Bone Marrow Transplantation in Acute Leukemia: Results of a Survey by the European Cooperative Group for Blood and Marrow Transplantation
28. Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03
29. A Cellular Therapy with Haploidentical Peripheral Hematopoietic STEM CELL Transplantation MAY be a Therapeutic Option in Patients with Relapsed Lymphoma with Chemorefractory Disease
30. Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease
31. Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.
32. Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study
33. Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: A case report
34. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
35. Plerixafor: what we still have to learn
36. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study
37. Core needle biopsy as a front line diagnostic approach for lymphoma patients
38. Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization
39. Concurrent Follicular Lymphoma At Diagnosis Has a Negative Impact On The Outcome Of Patients With Diffuse Large B Cell Lymphoma
40. Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03
41. Non-Hodgkin's Lymphomas Associated With Positive Hepatitis-C Virus Infection: A Prospective Multicentric Observational Study On Behalf Of The “Rete Ematologica Lombarda/Hematology Network Of Lombardia Region”
42. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma
43. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study
44. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
45. The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients
46. Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis
47. The More Effective and the More (bio) Similar: Plerixafor and Filgrastim XM02 (tevagastrim) As First Line PBSC Mobilization Strategy in Patients with Multiple Myeloma and Lymphomas Candidate to ABMT
48. Plerixafor and Filgrastim XM02 (Tevagastrim®) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation
49. Rituximab Plus Chlorambucil Compared with Chlorambucil and Prednisone In Patients with Untreated Follicular Lymphoma
50. Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.